Streetbeat News

Stock Prices

VICI

Mizuho analyst Haendel St. Juste has maintained a Buy rating on VICI Properties (NYSE:VICI) but has reduced the price target from $34 to $32.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:17 pm

SIMO

Silicon Motion Technology Corporation (NASDAQ:SIMO) announced a new organizational structure to support its global business growth. The company has created two business units: Client & Automotive Storage (CAS) and Enterprise Storage & Display Interface Solution (ESDI). Nelson S. Duann is appointed as Senior VP of the CAS unit, Alex Chou as Senior VP to lead the ESDI unit, and Robert Fan as Senior VP of Global Sales and President of SMI USA. The changes aim to foster faster innovation and stronger growth.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:17 pm

AGNC

NYMT

TRTX

The article highlights three high-yielding dividend stocks in the financial sector that have been rated by Wall Street's most accurate analysts. AGNC Investment Corp. (AGNC) has a dividend yield of 15.78% and received mixed ratings with a recent positive earnings report. TPG RE Finance Trust, Inc. (TRTX) offers a 15.74% yield but had a price target cut following downbeat sales. New York Mortgage Trust, Inc. (NYMT) yields 13.42% and also saw a price target adjustment after reporting weaker sales.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 1:14 pm

DPZ

Benchmark analyst Todd Brooks has upgraded Domino's Pizza (NYSE:DPZ) from Hold to Buy and set a new price target of $455.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:14 pm

MOBV

SVMH

SVMHW

SRIVARU Holding Limited has completed a business combination with Mobiv Acquisition Corp and will begin trading on Nasdaq under the ticker symbols SVMH and SVMHW. Mohanraj Ramasamy, a former Tesla executive and founder of SRIVARU, is now CEO of the combined entity. The company aims to capture a significant share of the Indian and global EV markets, leveraging its state-of-the-art technologies and capital-efficient business model. SRIVARU is positioned to benefit from the growing Indian EV market, expected to exceed $36 billion by 2027, and plans to provide detailed business updates soon.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:13 pm

ABBV

Goldman Sachs analyst Chris Shibutani has upgraded AbbVie (NYSE:ABBV) from Neutral to Buy and set a price target of $173.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:13 pm

NMTC

NeuroOne Medical Technologies Corporation (NMTC) has received FDA 510(k) clearance to market its OneRF Ablation System, which is used to create radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:12 pm

M

Macy's Inc (NYSE:M) shares surged 16% to $20.19 after a report that an investor group made a $5.8 billion buyout offer. The group, including Arkhouse Management and Brigade Capital Management, proposed to take Macy's private at $21 per share, a 32% premium over the recent close. Macy's has struggled against online competition, with its share price falling from $70 in 2015 to $17.39 recently. The stock has a 52-week range of $10.54 to $25.12.

Portfolio Pulse from Henry Khederian

December 11, 2023 | 1:12 pm

WSR

The District Court in Harris County, Texas dismissed all claims against Whitestone REIT (NYSE:WSR) by its former CEO, James C. Mastandrea, related to his termination. Mastandrea had filed a lawsuit seeking up to $25 million for alleged breach of contract and other claims. Whitestone's current CEO, Dave Holeman, expressed satisfaction with the court's decision, noting the removal of legal defense costs and a positive outlook for the company's future.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:11 pm

CRIS

Curis, Inc. (NASDAQ:CRIS) presented positive clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference. The study focuses on emavusertib (CA-4948), an IRAK4 inhibitor showing a safe profile and anti-cancer activity, particularly in patients with a FLT3 mutation. Results included substantial reductions in blast counts and manageable treatment-related adverse events. Notably, 2 out of 3 patients achieved a Complete Response with 300 mg BID dosage in a specific patient subset.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:09 pm